Podcast interview with Dr. Elvira Müller. EU joint HTA – decided, but how will it be executed and how should companies prepare
In Europe, there are at least as many reimbursement assessment processes in place as European…
CertaraFebruary 7, 2023
FDA awards new grants to support developing & assessing complex generic drugs
Certara’s Simcyp physiologically-based pharmacokinetic (PBPK) Simulator is being used to verify and expand biosimulation models…
CertaraFebruary 7, 2023
Artificial Intelligence: What is it & how can it accelerate rare disease drug development?
Large & complex information streams present opportunities for the AI data scientist to aid in…
CertaraFebruary 3, 2023
Machine learning model selection with Darwin in Pirana
Discover how to enhance machine learning model selection with Darwin in Pirana. Watch this on-demand…
CertaraFebruary 3, 2023
Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023
PRINCETON, N.J.— February 1, 2023-- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today…
CertaraFebruary 1, 2023
How Modeling & Simulation is Addressing the Immunogenicity Challenge: An academic nicety is now a drug development and regulatory differentiator
Learn how modeling and simulation can help drug developers overcome the immunogenicity challenge, a major…
CertaraJanuary 30, 2023
